Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

被引：0
作者：
Aseem Anand
Michael J. Morris
Steven M. Larson
David Minarik
Andreas Josefsson
John T. Helgstrand
Peter S. Oturai
Lars Edenbrandt
Martin Andreas Røder
Anders Bjartell
机构：
[1] Lund University,Department of Translational Medicine, Division of Urological Cancers
[2] Memorial Sloan Kettering Cancer Center,Department of Medicine
[3] Weil Cornell Medical College,Department of Radiology
[4] Memorial Sloan Kettering Cancer Center,Department of Radiation Physics, Skåne University Hospital
[5] Lund University,Department of Urology, Institute of Clinical Sciences
[6] Sahlgrenska Academy,Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet
[7] University of Copenhagen,Department of Clinical Physiology, Nuclear Medicine and PET
[8] Copenhagen University Hospital,Department of Nuclear Medicine
[9] Skåne University Hospital,Department of Urology
[10] Skåne University Hospital,undefined
来源：
EJNMMI Research | / 6卷
关键词：
Bone Scan Index (BSI); Imaging biomarker; Bone scan; Enzalutamide; Metastatic castration-resistant prostate cancer (mCRPC);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel
    Bilgetekin, Irem
    Basal, Fatma Bugdayci
    Cinkir, Havva Yesil
    Esin, Ece
    Oksuzoglu, Berna
    Demirci, Umut
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (08): : 815 - 821
  • [32] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sebastian Christoph Schmid
    Alexander Geith
    Alena Böker
    Robert Tauber
    Anna Katharina Seitz
    Markus Kuczyk
    Christoph von Klot
    Jürgen Erich Gschwend
    Axel Stuart Merseburger
    Margitta Retz
    Advances in Therapy, 2014, 31 : 234 - 241
  • [33] Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide
    Shiota, Masaki
    Machidori, Asako
    Abe, Tatsuro
    Monji, Keisuke
    Kashiwagi, Eiji
    Takeuchi, Ario
    Takahashi, Ryosuke
    Inokuchi, Junichi
    Yokomizo, Akira
    Naito, Seiji
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (12) : 1109 - 1115
  • [34] A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE
    Payne, Heather
    Robinson, Angus
    Rappe, Bernard
    Hilman, Serena
    De Giorgi, Ugo
    Joniau, Steven
    Bordonaro, Roberto
    Mallick, Stephane
    Dourthe, Louis-Marie
    Flores, Moises Mira
    Guma, Josep
    Baron, Benoit
    Duran, Aurea
    Pranzo, Alessandra
    Serikoff, Alexis
    Mott, David
    Herdman, Mike
    Pavesi, Marco
    De Santis, Maria
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (05) : 837 - 846
  • [35] Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide
    Fujmoto, Saizo
    Fujita, Kazutoshi
    Nishimoto, Mitsuhisa
    Hamaguchi, Mamoru
    Kuwahara, Ken
    Hashimoto, Mamoru
    Adomi, Shogo
    Minami, Takafumi
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    CANCER MEDICINE, 2023, 12 (03): : 3176 - 3179
  • [36] Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
    Altavilla, Amelia
    Casadei, Chiara
    Lolli, Cristian
    Menna, Cecilia
    Ravaglia, Giorgia
    Gurioli, Giorgia
    Farolfi, Alberto
    Brighi, Nicole
    Conteduca, Vincenza
    Burgio, Salvatore Luca
    Schepisi, Giuseppe
    Rossi, Lorena
    Gargiulo, Stefania
    Lisotti, Ivana
    De Giorgi, Ugo
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (17) : 2091 - 2099
  • [37] The role of enzalutamide in the treatment of castration-resistant prostate cancer
    Rawlinson, Alex
    Mohammed, Aza
    Miller, Marek
    Kunkler, Roger
    FUTURE ONCOLOGY, 2012, 8 (09) : 1073 - 1081
  • [38] Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
    Takashi Kawahara
    Yusuke Saigusa
    Shuko Yoneyama
    Masashi Kato
    Ippei Kojima
    Hiroshi Yamada
    Osamu Kamihira
    Kenichi Tabata
    Hideyasu Tsumura
    Masatsugu Iwamura
    Kazuhide Makiyama
    Hiroji Uemura
    Yasuhide Miyoshi
    BMC Cancer, 23
  • [39] The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide
    Nakamura, So
    Nagata, Masayoshi
    Nagaya, Naoya
    Ashizawa, Takeshi
    Hirano, Hisashi
    Lu, Yan
    Ide, Hisamitsu
    Horie, Shigeo
    CANCERS, 2024, 16 (04)
  • [40] PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide A retrospective case-report study
    Bosso, Davide
    Pagliuca, Martina
    Sonpavde, Guru
    Pond, Gregory
    Lucarelli, Giuseppe
    Rossetti, Sabrina
    Facchini, Gaetano
    Scagliarini, Sarah
    Carteni, Giacomo
    Daniele, Bruno
    Morelli, Franco
    Ferro, Matteo
    Puglia, Livio
    Izzo, Michela
    Montanaro, Vittorino
    Bellelli, Teresa
    Vitrone, Francesca
    De Placido, Sabino
    Buonerba, Carlo
    Di Lorenzo, Giuseppe
    MEDICINE, 2017, 96 (24)
12345